In a recent NJBiz article about harnessing data, Anthony Vecchione speaks to SVP – Life Sciences, V. “Bala” Balasubramanian about how bringing a new drug to market requires a sharp focus on safety, efficacy, quality and data.
Bala states, “Companies deal with massive amounts of data. Pharma and life sciences companies collect massive amounts of data which they need from a regulatory perspective. They need the data so support product development, to receive approvals from regulatory, measure effectiveness, and track manufacturing quality.”
According to Bala, the challenge for pharma and life sciences professionals is how to collect, curate and harness the data in meaningful ways and improve business processes.
He explains, “At Orion, we work across the life cycle of pharma and life sciences. We work with pharma companies to transform their R&D, manufacturing and commercialization processes with the use of digital technologies. Once they get to market and consumers are given the medication, we support companies with the effective tracking of the safety profile of products.”
When asked about the increased demand from pharma and life sciences companies to manage regulatory requirements, Bala highlights Orion’s digital platform, ReALM®, specifically how it “helps companies navigate through ever-changing regulations more effectively instead of managing them in spreadsheets.”
Read the full article here.
